We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Read MoreHide Full Article
Key Takeaways
Roche licensed and will co-develop bexobrutideg across hematology, immunology and neurology.
Bexobrutideg may enter phase III in second-line CLL in 2026 after encouraging early trial results.
Nurix gets $700M upfront; Roche leads ex-U.S. commercialization and funds 60% of development costs.
Roche (RHHBY - Free Report) has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics (NRIX - Free Report) to co-develop and co-commercialize bexobrutideg (NX-5948) across malignant hematology, immunology and neurology indications.
The deal expands Roche’s hematology pipeline while providing opportunities to advance the therapy across immunology and neurology indications. Shares of NRIX are up in pre-market trading on the collaboration news.
Year to date, shares of RHHBY have lost 0.2% against the industry’s growth of 4.5%.
Image Source: Zacks Investment Research
More on RHHBY-NRIX Collaboration
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies and diseases in immunology and neurology.
Bexobrutideg employs a novel protein degradation mechanism that eliminates BTK rather than simply inhibiting it, potentially overcoming resistance associated with currently available BTK inhibitors.
The drug is expected to enter phase III testing in second-line chronic lymphocytic leukemia (CLL) later in 2026. Early clinical results suggest the therapy could deliver superior efficacy and tolerability compared with existing BTK inhibitors while potentially overcoming key resistance mechanisms. The collaboration also enables Roche to leverage its leading hematology franchise to accelerate the drug’s development and commercialization.
Under the agreement, Nurix will receive $700 million upfront and could earn up to $2.3 billion in total through development, regulatory, and commercial milestone payments. Roche will fund 60% of development costs, with Nurix covering the remaining 40%.
The companies will jointly commercialize bexobrutideg in the United States, sharing profits and losses equally. Outside the United States, Roche will lead commercialization, while Nurix will receive tiered royalties ranging from the low- to high-teens.
The companies expect the transaction to be completed in the third quarter of 2026.
RHHBY’s Efforts to Diversify Pipeline
While Roche’s performance in the first quarter was weighed down by unfavorable foreign-exchange movements, the company’s underlying operational performance remained solid. Strong growth from key products helped offset declining revenues from legacy drugs.
MS drug Ocrevus and ophthalmology drug Vabysmo continued their stellar performances. Growth in hemophilia treatment Hemlibra and breast cancer drug Phesgo also boosted RHHBY’s top line.
Roche has a strong and diversified pipeline spanning multiple therapeutic modalities.
Bexobrutideg has delivered encouraging results as a monotherapy in clinical trials for B-cell malignancies.
The collaboration adds to Roche’s oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis).
The FDA recently accepted and granted Priority Review to its new drug application for giredestrant, an investigational oral selective estrogen receptor degrader (SERD), for the adjuvant treatment of adults with ER-positive, HER2-negative stage I–III breast cancer. A regulatory decision is expected by Nov. 30, 2026.
A tentative approval of breast cancer candidate giredestrant could serve as a meaningful catalyst for the stock.
While Roche is making efforts to further diversify its broad portfolio, the company remains a late entrant into the highly competitive obesity market, which is currently dominated by other large-cap pharma players, such as Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) .
Roche’s obesity assets include enicepatide (CT-388) and petrelintide. Roche is rapidly advancing its obesity pipeline, with both enicepatide and petrelintide progressing into phase III trials and a multi-arm phase II combination study set to begin in mid-2026.
Eli Lilly currently leads the obesity market with its tirzepatide-based dual GLP-1/GIP receptor agonists, Mounjaro and Zepbound.
Arch rival Novo Nordisk commands a strong position with its semaglutide-based GLP-1 therapies, Ozempic and Wegovy, used in type II diabetes and obesity.
Both LLY and NVO generate a major chunk of their total revenues from their respective cardiometabolic drugs.
View the Zacks #1 Rank List
Image: Bigstock
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Key Takeaways
Roche (RHHBY - Free Report) has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics (NRIX - Free Report) to co-develop and co-commercialize bexobrutideg (NX-5948) across malignant hematology, immunology and neurology indications.
The deal expands Roche’s hematology pipeline while providing opportunities to advance the therapy across immunology and neurology indications. Shares of NRIX are up in pre-market trading on the collaboration news.
Year to date, shares of RHHBY have lost 0.2% against the industry’s growth of 4.5%.
Image Source: Zacks Investment Research
More on RHHBY-NRIX Collaboration
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies and diseases in immunology and neurology.
Bexobrutideg employs a novel protein degradation mechanism that eliminates BTK rather than simply inhibiting it, potentially overcoming resistance associated with currently available BTK inhibitors.
The drug is expected to enter phase III testing in second-line chronic lymphocytic leukemia (CLL) later in 2026. Early clinical results suggest the therapy could deliver superior efficacy and tolerability compared with existing BTK inhibitors while potentially overcoming key resistance mechanisms. The collaboration also enables Roche to leverage its leading hematology franchise to accelerate the drug’s development and commercialization.
Under the agreement, Nurix will receive $700 million upfront and could earn up to $2.3 billion in total through development, regulatory, and commercial milestone payments. Roche will fund 60% of development costs, with Nurix covering the remaining 40%.
The companies will jointly commercialize bexobrutideg in the United States, sharing profits and losses equally. Outside the United States, Roche will lead commercialization, while Nurix will receive tiered royalties ranging from the low- to high-teens.
The companies expect the transaction to be completed in the third quarter of 2026.
RHHBY’s Efforts to Diversify Pipeline
While Roche’s performance in the first quarter was weighed down by unfavorable foreign-exchange movements, the company’s underlying operational performance remained solid. Strong growth from key products helped offset declining revenues from legacy drugs.
MS drug Ocrevus and ophthalmology drug Vabysmo continued their stellar performances. Growth in hemophilia treatment Hemlibra and breast cancer drug Phesgo also boosted RHHBY’s top line.
Roche has a strong and diversified pipeline spanning multiple therapeutic modalities.
Bexobrutideg has delivered encouraging results as a monotherapy in clinical trials for B-cell malignancies.
The collaboration adds to Roche’s oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis).
The FDA recently accepted and granted Priority Review to its new drug application for giredestrant, an investigational oral selective estrogen receptor degrader (SERD), for the adjuvant treatment of adults with ER-positive, HER2-negative stage I–III breast cancer. A regulatory decision is expected by Nov. 30, 2026.
A tentative approval of breast cancer candidate giredestrant could serve as a meaningful catalyst for the stock.
While Roche is making efforts to further diversify its broad portfolio, the company remains a late entrant into the highly competitive obesity market, which is currently dominated by other large-cap pharma players, such as Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) .
Roche’s obesity assets include enicepatide (CT-388) and petrelintide. Roche is rapidly advancing its obesity pipeline, with both enicepatide and petrelintide progressing into phase III trials and a multi-arm phase II combination study set to begin in mid-2026.
Eli Lilly currently leads the obesity market with its tirzepatide-based dual GLP-1/GIP receptor agonists, Mounjaro and Zepbound.
Arch rival Novo Nordisk commands a strong position with its semaglutide-based GLP-1 therapies, Ozempic and Wegovy, used in type II diabetes and obesity.
Both LLY and NVO generate a major chunk of their total revenues from their respective cardiometabolic drugs.
RHHBY’s Zacks Rank
Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.